These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 33422172)

  • 41. Effect of the phosphodiesterase 4 inhibitor apremilast on cardiometabolic outcomes in psoriatic disease-results of the Immune Metabolic Associations in Psoriatic Arthritis study.
    Ferguson LD; Cathcart S; Rimmer D; Semple G; Brooksbank K; Paterson C; Brown R; Harvie J; Gao X; Radjenovic A; Welsh P; McInnes IB; Sattar N; Siebert S
    Rheumatology (Oxford); 2022 Mar; 61(3):1026-1034. PubMed ID: 34097014
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phosphodiesterase-4 Inhibition Reduces Cutaneous Inflammation and IL-1β Expression in a Psoriasiform Mouse Model but Does Not Inhibit Inflammasome Activation.
    Meier-Schiesser B; Mellett M; Ramirez-Fort MK; Maul JT; Klug A; Winkelbeiner N; Fenini G; Schafer P; Contassot E; French LE
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884681
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis.
    Schafer P
    Biochem Pharmacol; 2012 Jun; 83(12):1583-90. PubMed ID: 22257911
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Apremilast for psoriasis treatment.
    Carrascosa JM; Del-Alcazar E
    G Ital Dermatol Venereol; 2020 Aug; 155(4):421-433. PubMed ID: 32545946
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Improvement of Nail and Scalp Psoriasis Using Apremilast in Patients With Chronic Psoriasis: Phase 2b and 3, 52-Week Randomized, Placebo-Controlled Trial Results.
    Nguyen CM; Leon A; Danesh M; Beroukhim K; Wu JJ; Koo J
    J Drugs Dermatol; 2016 Mar; 15(3):272-6. PubMed ID: 26954311
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Apremilast for the treatment of psoriatic arthritis.
    Souto A; Gómez-Reino JJ
    Expert Rev Clin Immunol; 2015; 11(12):1281-90. PubMed ID: 26503917
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Emerging Oral Immunomodulators for the Treatment of Psoriasis: A Review of Phase III Clinical Trials for Apremilast and Tofacitinib.
    McAndrew R; Levin E; Koo J
    J Drugs Dermatol; 2015 Aug; 14(8):786-92. PubMed ID: 26267722
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1).
    Schafer PH; Chen P; Fang L; Wang A; Chopra R
    J Immunol Res; 2015; 2015():906349. PubMed ID: 25973439
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).
    Papp K; Reich K; Leonardi CL; Kircik L; Chimenti S; Langley RG; Hu C; Stevens RM; Day RM; Gordon KB; Korman NJ; Griffiths CE
    J Am Acad Dermatol; 2015 Jul; 73(1):37-49. PubMed ID: 26089047
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Apremilast Uses and Relevance to the Military.
    Hathaway NE; Lyford WH
    Cutis; 2021 Apr; 107(4):216-220. PubMed ID: 34096849
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast.
    Gottlieb AB; Strober B; Krueger JG; Rohane P; Zeldis JB; Hu CC; Kipnis C
    Curr Med Res Opin; 2008 May; 24(5):1529-38. PubMed ID: 18419879
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of apremilast in chronic cutaneous sarcoidosis.
    Baughman RP; Judson MA; Ingledue R; Craft NL; Lower EE
    Arch Dermatol; 2012 Feb; 148(2):262-4. PubMed ID: 22004880
    [No Abstract]   [Full Text] [Related]  

  • 53. Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis.
    Papadavid E; Rompoti N; Theodoropoulos K; Kokkalis G; Rigopoulos D
    J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):1173-1179. PubMed ID: 29388335
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.
    Schafer PH; Parton A; Capone L; Cedzik D; Brady H; Evans JF; Man HW; Muller GW; Stirling DI; Chopra R
    Cell Signal; 2014 Sep; 26(9):2016-29. PubMed ID: 24882690
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).
    Rich P; Gooderham M; Bachelez H; Goncalves J; Day RM; Chen R; Crowley J
    J Am Acad Dermatol; 2016 Jan; 74(1):134-42. PubMed ID: 26549249
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Skin involvement in patients with psoriatic arthritis: preliminary results of treatment with apremilast in real world setting.
    Radi G; Campanati A; Diotallevi F; Molinelli E; Offidani A
    G Ital Dermatol Venereol; 2019 Apr; 154(2):166-169. PubMed ID: 30229640
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Apremilast in dermatology: A review of literature.
    Nassim D; Alajmi A; Jfri A; Pehr K
    Dermatol Ther; 2020 Nov; 33(6):e14261. PubMed ID: 32876993
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Apremilast for the off-label treatment of lichenoid and interface dermatoses.
    Ravichandran S; Kheterpal MK
    J Am Acad Dermatol; 2020 Nov; 83(5):1489-1491. PubMed ID: 32497705
    [No Abstract]   [Full Text] [Related]  

  • 59. Otezla, Warts and All, Racks Up Sales and Eyes Blockbuster Status.
    Reinke T
    Manag Care; 2017 Oct; 26(10):8-9. PubMed ID: 29068290
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A multicentre open-label study of apremilast in palmoplantar pustulosis (APLANTUS).
    Wilsmann-Theis D; Kromer C; Gerdes S; Linker C; Magnolo N; Sabat R; Reich K; Mössner R
    J Eur Acad Dermatol Venereol; 2021 Oct; 35(10):2045-2050. PubMed ID: 34077577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.